Known active infections Patients with clinically significant active infections Active clinically serious infections or other serious uncontrolled medical conditions Uncontrolled infections No active serious infections or other conditions precluding chemotherapy Active or uncontrolled infections Active or uncontrolled infections Any evidence of serious active infections; any infections being treated must complete antibiotic therapy at least days before planned first dose. Uncontrolled active systemic infections Active infections Active or uncontrolled infections Infections such as pneumonia or wound infections that would preclude protocol therapy. Uncontrolled infections. No uncontrolled infections; No uncontrolled infections; FOR ALL PHASES (Ib AND II): Uncontrolled infection; active, clinically serious infections (> CTCAE grade ) No active infections Active infections within hours of study entry Active uncontrolled acute infections Evidence of active infections =< days prior to initiation of study drug therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry) Known active infections CELL PROCUREMENT: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-respiratory syncytial virus (RSV), isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded LYMPHODEPLETION: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-RSV, isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded Active, clinically serious infections or other serious uncontrolled medical conditions Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. Uncontrolled infections Active or uncontrolled infections Active or uncontrolled infections Not have active, uncontrolled infections Active, uncontrolled infections Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. Active clinically serious infections (> CTCAE grade ) Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least weeks before study entry Active known clinically serious infections Evidence of active infections ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Evidence of active infections Uncontrolled infections Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. Patients with active, uncontrolled infections Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections. Active and uncontrolled infections Patients with untreated or uncontrolled infections No uncontrolled infections as determined by the investigator Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved Recent or ongoing serious infections within weeks Evidence of active infections Patients with serious uncontrolled infections will not be eligible Patients with serious uncontrolled infections at the time of planned transplant will be excluded Known infections: Has uncontrolled active infection of any kind. (Patients with infections controlled by active antibiotic treatment are eligible). Active and uncontrolled systemic infections. Active clinically serious infections (? CTCAE v. Grade ). Active infections Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least weeks before study entry DONOR: Current serious systemic illness including uncontrolled infections Current uncontrolled infections. Active clinically serious infections or other serious uncontrolled medical conditions Uncontrolled infections Patients with serious uncontrolled infections at the time of transplant will be excluded Active or uncontrolled infections Poor medical risk because of systemic diseases (e.g. active uncontrolled infections) in addition to the qualifying disease under study. Active, unresolved infections Severe infections at the time of randomization Active uncontrolled infections Active clinically serious infections (> grade ) Active clinically serious infections > CTCAE Grade Infections such as pneumonia or wound infections that would preclude protocol therapy Active clinically serious infections Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least weeks before study entry Any evidence of serious active infections Concurrent serious uncontrolled infections requiring treatment or known infection with HIV Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. Uncontrolled infections Patients must not have any active infections Patients with severe systemic infections Uncontrolled systemic disease like active infections Patients with active clinical infections Known active infections c. Active or failed to control serious infections (CTCAE version . > grade infections) Known active infections DONOR: Current serious systemic illness including uncontrolled infections Any evidence of serious active infections. DONOR: No active or chronic infections Clinically significant uncontrolled illness or active infections Active or uncontrolled infections . Any evidence of serious active infections. Patients with active infections, including HIV, will be excluded Any evidence of serious active infections Infections Active clinically serious infections of > Grade and/or active infections that require treatment with systemic agent Severe systemic diseases or active uncontrolled infections Recent infections not meeting the criteria for severe infections within weeks prior to Cycle , Day Participants who have active, uncontrolled infections. Uncontrolled (not being treated) infections at the time of cytoreduction Severe infections within weeks prior to Day Active clinically serious infections of > Grade Patients must have no evidence of active infections at the time of transplantation Patient with active infections Active and uncontrolled infections Patients with uncontrolled infections Patients with ongoing symptomatic dental infections active infections of the oral cavity Active infection (except mild upper respiratory infections) Patients with clinically significant active infections Patients with active urinary tract infections Patients should not have active infections or concurrent neoplastic disease except for skin cancer Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease. Active infections of oral cavity Patients with active infections. Active, uncontrolled infections within days of study entry requiring systemic therapy.